Abstract
The outstanding physio-pathological role played by integrin receptors in living subjects motivates the enormous interest shown by scientists worldwide for this topic. More than twenty years of research has spanned across the structural and functional elucidation of these proteins and over their antagonism-based biomedical applications. The proof-ofconcept stage, aimed at identifying potent inhibitors, covered a decade of studies, and paved the way for a more advanced era of research where these antagonist molecules were thrown into the deep end of applicative studies. This review intends to summarize the major efforts conducted thus far and focuses on the design, synthesis and biomedical applications of cyclic RGD-containing αvβ3 integrin antagonists, in both their small and macromolecular formats. In particular, Chapters 1 and 2 offer a comprehensive outlook on the rational basis for the design of integrin inhibitors, Chapter 3 chronicles the biological and medical applications of monofunctional RGD integrin ligands both in their monomeric and multimeric asset, and Chapter 4 illustrates the potential of RGD-based multifunctional systems in molecular medicine.
Keywords: Integrins, design of RGD ligands, cancer therapy and imaging, targeted drug delivery, multimodality, integrin targeted nanoparticles
Current Medicinal Chemistry
Title: Targeting αvβ3 Integrin: Design and Applications of Mono- and Multifunctional RGD-Based Peptides and Semipeptides
Volume: 17 Issue: 13
Author(s): L. Auzzas, F. Zanardi, L. Battistini, P. Burreddu, P. Carta, G. Rassu, C. Curti and G. Casiraghi
Affiliation:
Keywords: Integrins, design of RGD ligands, cancer therapy and imaging, targeted drug delivery, multimodality, integrin targeted nanoparticles
Abstract: The outstanding physio-pathological role played by integrin receptors in living subjects motivates the enormous interest shown by scientists worldwide for this topic. More than twenty years of research has spanned across the structural and functional elucidation of these proteins and over their antagonism-based biomedical applications. The proof-ofconcept stage, aimed at identifying potent inhibitors, covered a decade of studies, and paved the way for a more advanced era of research where these antagonist molecules were thrown into the deep end of applicative studies. This review intends to summarize the major efforts conducted thus far and focuses on the design, synthesis and biomedical applications of cyclic RGD-containing αvβ3 integrin antagonists, in both their small and macromolecular formats. In particular, Chapters 1 and 2 offer a comprehensive outlook on the rational basis for the design of integrin inhibitors, Chapter 3 chronicles the biological and medical applications of monofunctional RGD integrin ligands both in their monomeric and multimeric asset, and Chapter 4 illustrates the potential of RGD-based multifunctional systems in molecular medicine.
Export Options
About this article
Cite this article as:
Auzzas L., Zanardi F., Battistini L., Burreddu P., Carta P., Rassu G., Curti C. and Casiraghi G., Targeting αvβ3 Integrin: Design and Applications of Mono- and Multifunctional RGD-Based Peptides and Semipeptides, Current Medicinal Chemistry 2010; 17 (13) . https://dx.doi.org/10.2174/092986710790936301
DOI https://dx.doi.org/10.2174/092986710790936301 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Tailored Mesoporous Silica Nanoparticles for Controlled Drug Delivery: Platform Fabrication, Targeted Delivery, and Computational Design and Analysis
Mini-Reviews in Medicinal Chemistry Drug Binding Domains of MRP1 (ABCC1) as Revealed by Photoaffinity Labeling
Current Medicinal Chemistry - Anti-Cancer Agents Nanoradiopharmaceuticals for Bone Cancer Metastasis Imaging
Current Cancer Drug Targets Nanofibers: New Insights for Drug Delivery and Tissue Engineering
Current Topics in Medicinal Chemistry Toxicogenomics to Improve Comprehension of the Mechanisms Underlying Responses of In Vitro and In Vivo Systems to Nanomaterials: A Review
Current Genomics Natural Products as Leads for Tuberculosis Drug Development
Current Topics in Medicinal Chemistry Editorial
Current Pharmaceutical Biotechnology Potential Health Benefits of Berries
Current Nutrition & Food Science Lafora Progressive Myoclonus Epilepsy: Recent Insights into Cell Degeneration
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Biomarkers Downstream of RAS: A Search for Robust Transcriptional Targets
Current Cancer Drug Targets The Renin Angiotensin System in the Regulation of Angiogenesis
Current Pharmaceutical Design TAT-Liposomes: A Novel Intracellular Drug Carrier
Current Protein & Peptide Science Evaluation of Natural and Synthetic Compounds from East Asiatic Folk Medicinal Plants on the Mediation of Cancer
Anti-Cancer Agents in Medicinal Chemistry Genetic Alterations in Poorly Differentiated and Undifferentiated Thyroid Carcinomas
Current Genomics Assessment of the Mitotic Spindle Assembly Checkpoint (SAC) as the Target of Anticancer Therapies
Current Cancer Drug Targets Silencing of Disease-related Genes by Small Interfering RNAs
Current Molecular Medicine Supercritical Fluid Particle Design for Poorly Water-soluble Drugs (Review)
Current Pharmaceutical Design A Comparative Molecular Field (CoMFA) Studies on Carbonic Anhydrase Inhibitor hCA IX-Tumor-Associated (Hypoxia)
Letters in Drug Design & Discovery Quality Assessment of Diagnostic Methods Employed for Suspected Lung Cancer
Current Respiratory Medicine Reviews Apicidin Inhibited Proliferation and Invasion and Induced Apoptosis via Mitochondrial Pathway in Non-small Cell Lung Cancer GLC-82 Cells
Anti-Cancer Agents in Medicinal Chemistry